Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "real-life"
- PMID: 33484755
- DOI: 10.1016/j.pnpbp.2021.110250
Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "real-life"
Abstract
First generation antipsychotics (FGAs) are more likely to induce extrapyramidal side-effects (EPS) than second generation antipsychotics (SGAs), and EPS have been shown associated to cognitive deficits in schizophrenia. So far, no study has explored the relationships between EPS and social cognition (SC) in people with schizophrenia. Therefore, we assessed the prevalence of EPS in a large sample of drug-treated community-dwelling persons with schizophrenia and explored their relationships with patients' neurocognitive and SC abilities. 875 patients underwent EPS, psychopathological, neurocognitive and SC assessments by means of standardized measures. Relationships between EPS, psychopathology and neurocognitive and SC measures were investigated by correlation tests. Moreover, a partial correlation network was computed by means of a network analysis. 256 patients were treated with FGAs alone or in combination with SGA and 619 with SGAs. EPS were significantly more frequent in FGA-treated group than in the SGA-treated one. Patients with EPS disclosed a more severe psychopathology and were more impaired in neurocognitive and SC measures compared to those without EPS. Disorganization, expressive deficit, and duration of illness were significantly associated to both neurocognitive and SC measures while EPS were associated to neurocognitive measures only. The network analysis showed that parkinsonism was the sole EPS directly connected to both psychopathological and neurocognitive indices whereas no direct connection emerged between EPS and SC measures. Present findings confirm that EPS are still present in the era of SGAs and contribute, together with other clinical variables, to the neurocognitive but not to the SC impairment of patients with schizophrenia.
Keywords: Antipsychotics; Extrapyramidal symptoms; Neurocognition; Schizophrenia; Social cognition.
Copyright © 2021 Elsevier Inc. All rights reserved.
Similar articles
-
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.Psychopharmacology (Berl). 2004 Oct;176(1):94-100. doi: 10.1007/s00213-004-1866-y. Epub 2004 Apr 9. Psychopharmacology (Berl). 2004. PMID: 15083255
-
Evolution of antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia in the real-life: A 4-year follow-up naturalistic study.Schizophr Res. 2022 Oct;248:279-286. doi: 10.1016/j.schres.2022.08.015. Epub 2022 Sep 15. Schizophr Res. 2022. PMID: 36116319
-
The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.J Clin Psychiatry. 1998 Feb;59(2):69-75. doi: 10.4088/jcp.v59n0205. J Clin Psychiatry. 1998. PMID: 9501888 Clinical Trial.
-
An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.Hum Psychopharmacol. 2007 Jul;22(5):315-25. doi: 10.1002/hup.853. Hum Psychopharmacol. 2007. PMID: 17542047 Review.
-
Antipsychotics in the treatment of schizophrenia: an overview.J Clin Psychiatry. 2011;72 Suppl 1:4-8. doi: 10.4088/JCP.10075su1.01. J Clin Psychiatry. 2011. PMID: 22217436 Review.
Cited by
-
Shared Biological Pathways between Antipsychotics and Omega-3 Fatty Acids: A Key Feature for Schizophrenia Preventive Treatment?Int J Mol Sci. 2021 Jun 26;22(13):6881. doi: 10.3390/ijms22136881. Int J Mol Sci. 2021. PMID: 34206945 Free PMC article. Review.
-
Factors influencing the outcome of integrated therapy approach in schizophrenia: A narrative review of the literature.Front Psychiatry. 2022 Aug 30;13:970210. doi: 10.3389/fpsyt.2022.970210. eCollection 2022. Front Psychiatry. 2022. PMID: 36117655 Free PMC article. Review.
-
Validation of the Chinese Version of the Schizophrenia Cognition Rating Scale.Psychiatry Investig. 2022 Jul;19(7):511-518. doi: 10.30773/pi.2021.0322. Epub 2022 Jul 21. Psychiatry Investig. 2022. PMID: 35903053 Free PMC article.
-
Extrapyramidal symptoms predict cognitive performance after first-episode psychosis.Schizophrenia (Heidelb). 2022 Aug 4;8(1):64. doi: 10.1038/s41537-022-00270-8. Schizophrenia (Heidelb). 2022. PMID: 35927423 Free PMC article.
-
Guideline concordant screening and monitoring of extrapyramidal symptoms in patients prescribed antipsychotic medication: a protocol for a systematic literature review and narrative synthesis.BMJ Open. 2024 Sep 12;14(9):e087632. doi: 10.1136/bmjopen-2024-087632. BMJ Open. 2024. PMID: 39266320 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous